Alpelisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
97.22
Gini
0.720
CATDS
0.021
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Alpelisib. Strongest target: RET at 99.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 99.6% | 0.4% |
| 2 | TRKB | 99.3% | 0.7% |
| 3 | TRKC | 99.3% | 0.7% |
| 4 | FGFR2 | 98.9% | 1.1% |
| 5 | FGFR1 | 98.7% | 1.3% |
| 6 | FGFR3 | 98.6% | 1.4% |
| 7 | TRKA | 97.5% | 2.5% |
| 8 | ROS_ROS1 | 97.1% | 2.9% |
| 9 | FGFR4 | 96.8% | 3.2% |
| 10 | JAK2 | 96.6% | 3.4% |
| 11 | JAK1 | 92.2% | 7.8% |
| 12 | DDR1 | 87.6% | 12.4% |
| 13 | FLT3 | 82.6% | 17.4% |
| 14 | EGFR | 81.3% | 18.7% |
| 15 | ALK | 80.7% | 19.3% |
| 16 | TXK | 80.0% | 20.0% |
| 17 | ERBB4_HER4 | 70.6% | 29.4% |
| 18 | MUSK | 70.2% | 29.8% |
| 19 | BMX_ETK | 68.9% | 31.1% |
| 20 | BLK | 67.4% | 32.6% |
Selectivity landscape
Where Alpelisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Alpelisib.
Annotations
Sign in to read and post annotations.
Loading…